Novo Nordisk A/S

NYSE:NVO

Drug Manufacturers - General

Healthcare
$39.43 -1.09%

-$0.48 today

Market cap
$173.82B
Beta
0.35
P/E (TTM)
10.2
EPS (TTM)
$27.45
Dividend yield
4.18%
52W Low $35.12High $74.38

Volume 16.12M

Average 16.05M

NVO Effect of Forex Changes

Change in reported cash caused by exchange-rate movements on foreign-currency balances.

Novo Nordisk A/SNYSE: NVO

Effect of Forex Changes · Q2 FY2026 · quarter ended Jun 2026

Effect of forex changes turns positive

Q2 FY2026 effect of forex changes was DKK 52M, compared with -DKK 810M a year earlier. Trailing-twelve-month effect of forex changes was -DKK 55M. Over 3 fiscal years it compounded at +45.1% a year.

Context

  • Effect of forex changes amounted to 0.2% of revenue in FY2025, unchanged from a year earlier.
  • Effect of forex changes increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly effect of forex changes holds near DKK 52M or moves back toward the trailing-twelve-month quarterly average of -DKK 13.75M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
DKK 52M+118.8% QoQ
Last fiscal yearDec 2025
-DKK 727M-259.8% YoY
LTMJun 2026
-DKK 55M-89.6% YoY
Effect of Forex Changes past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+106.4%——
1 year-259.8%——
3-year CAGR+45.1%——
5-year CAGR——
10-year CAGR——

Effect of Forex Changes history

DKK · from the cash flow

Latest · FY2025
(727M) DKK
Year-over-year change
-259.8%

Effect of Forex Changes vs competitors

How NVO compares with its peers on the latest reported figures

  • Peers report in different currencies, so effect of forex changes is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -89.6% is the 6th highest of 9, against a peer median of +22.5%.
  • Effect of forex changes amounts to 0.0% of revenue for NVO, versus a peer median of 0.0%.
NVO Competitors
Effect of Forex Changes for NVO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNYSanofiLTM Jun 2026€142.06M EUR+810.3%+375.9%0.3%
GSKGSK plcLTM Jun 2026£111.42M GBP+74.1%-62.8%0.3%
NVONovo Nordisk A/SLTM Jun 2026DKK 55M DKK-89.6%+45.1%0.0%
AZNAstraZeneca PLCLTM Sep 2026$37.86M USD+262.5%—0.1%
MRKMerck & Co., Inc.LTM Jun 2026$33M USD-92.8%—0.0%
LLYEli Lilly and CompanyLTM Jun 2026$20.4M USD-109.9%—0.0%
PFEPfizer Inc.LTM Jun 2026$17M USD-29.2%—0.0%
ABBVAbbVie Inc.LTM Jun 2026$16M USD-1700.0%—0.0%
JNJJohnson & JohnsonLTM Sep 2026$13M USD+165.0%—0.0%
AMGNAmgen Inc.LTM Jun 2026$0 USD——0.0%
Peer median (excluding NVO) —+22.5%+156.6%0.0%

Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

DKK
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income47.76B55.53B83.68B100.99B102.43B
Depreciation & Amortization6.03B7.36B9.41B19.11B21.98B
Deferred Income Tax11.32B13.54B20.99B26.2B28.11B
Stock-Based Compensation1.04B1.54B2.15B2.29B0
Change in Working Capital(8.66B)(5.54B)(12.25B)2.59B3.74B
Accounts Receivables(12.91B)(10.82B)(14.21B)(14.31B)0
Inventory(1.09B)(4.77B)(7.42B)(9.04B)0
Accounts Payables3.15B6.72B10.02B3.24B0
Other Working Capital2.19B3.34B(631M)22.7B3.74B
Other Non-Cash Items(2.49B)6.46B4.92B(30.21B)(37.16B)
Operating Cash Flow55B78.89B108.91B120.97B119.1B
Capital Expenditures(7.39B)(14.75B)(38.9B)(51.31B)(90.11B)
Acquisitions (Net)(18.28B)(7.08B)0(82.16B)1B
Purchases of Investments(7.11B)(9.74B)(13.29B)(19.81B)(723M)
Sales of Investments1.17B6.65B8.29B24.39B10.67B
Other Investing Activities4M(2.61B)(13.09B)(4.15B)(29.97B)
Investing Cash Flow(31.61B)(24.92B)(43.89B)(128.9B)(79.16B)
Debt Repayment15.47B(2.41B)(1.47B)73.06B24.74B
Common Stock Issued00000
Common Stock Repurchased(19.45B)(24.09B)(29.92B)(20.18B)(1.39B)
Dividends Paid(21.52B)(25.3B)(31.77B)(44.14B)(51.76B)
Other Financing Activities00000
Financing Cash Flow(25.49B)(51.8B)(63.16B)8.74B(28.41B)
Effect of Forex Changes591M(238M)(119M)455M(727M)
Net Change in Cash(1.51B)1.93B1.74B1.26B10.81B
Free Cash Flow47.62B64.13B70.01B69.66B28.99B

Novo Nordisk A/S

NYSE:NVO

Intrinsic Alpha fair value

Locked

Current Price

$39.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.